[Highly selective virostatic therapy. Influenza wave could have been stopped].
Identifieur interne : 000530 ( Main/Curation ); précédent : 000529; suivant : 000531[Highly selective virostatic therapy. Influenza wave could have been stopped].
Auteurs : Melanie Leshel-HauzenederSource :
- MMW Fortschritte der Medizin [ 1438-3276 ] ; 2003.
Descripteurs français
- KwdFr :
- Acétamides (administration et posologie), Acétamides (usage thérapeutique), Allemagne (épidémiologie), Antienzymes (administration et posologie), Antienzymes (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Cytokines (sang), Endothélium vasculaire (physiopathologie), Essais cliniques de phase II comme sujet, Essais cliniques de phase III comme sujet, Facteurs temps, Fibrinogène (analyse), Grippe humaine (), Grippe humaine (mortalité), Grippe humaine (physiopathologie), Grippe humaine (sang), Grippe humaine (traitement médicamenteux), Grippe humaine (épidémiologie), Humains, Oséltamivir, Placebo, Résultat thérapeutique, Sialidase (administration et posologie), Sialidase (antagonistes et inhibiteurs).
- MESH :
- administration et posologie : Acétamides, Antienzymes, Antiviraux, Sialidase.
- analyse : Fibrinogène.
- antagonistes et inhibiteurs : Sialidase.
- mortalité : Grippe humaine.
- physiopathologie : Endothélium vasculaire, Grippe humaine.
- sang : Cytokines, Grippe humaine.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Acétamides, Antienzymes, Antiviraux.
- épidémiologie : Allemagne, Grippe humaine.
- Essais cliniques de phase II comme sujet, Essais cliniques de phase III comme sujet, Facteurs temps, Grippe humaine, Humains, Oséltamivir, Placebo, Résultat thérapeutique.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Acetamides (administration & dosage), Acetamides (therapeutic use), Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Cytokines (blood), Endothelium, Vascular (physiopathology), Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (therapeutic use), Fibrinogen (analysis), Germany (epidemiology), Humans, Influenza, Human (blood), Influenza, Human (complications), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (mortality), Influenza, Human (physiopathology), Neuraminidase (administration & dosage), Neuraminidase (antagonists & inhibitors), Oseltamivir, Placebos, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Acetamides, Antiviral Agents, Enzyme Inhibitors, Neuraminidase.
- chemical , analysis : Fibrinogen.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , blood : Cytokines.
- chemical , therapeutic use : Acetamides, Antiviral Agents, Enzyme Inhibitors.
- geographic , epidemiology : Germany.
- blood : Influenza, Human.
- complications : Influenza, Human.
- drug therapy : Influenza, Human.
- epidemiology : Influenza, Human.
- mortality : Influenza, Human.
- physiopathology : Endothelium, Vascular, Influenza, Human.
- Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Humans, Oseltamivir, Placebos, Time Factors, Treatment Outcome.
PubMed: 15101538
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000530
Links to Exploration step
pubmed:15101538Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Highly selective virostatic therapy. Influenza wave could have been stopped].</title>
<author><name sortKey="Leshel Hauzeneder, Melanie" sort="Leshel Hauzeneder, Melanie" uniqKey="Leshel Hauzeneder M" first="Melanie" last="Leshel-Hauzeneder">Melanie Leshel-Hauzeneder</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:15101538</idno>
<idno type="pmid">15101538</idno>
<idno type="wicri:Area/Main/Corpus">000530</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000530</idno>
<idno type="wicri:Area/Main/Curation">000530</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000530</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Highly selective virostatic therapy. Influenza wave could have been stopped].</title>
<author><name sortKey="Leshel Hauzeneder, Melanie" sort="Leshel Hauzeneder, Melanie" uniqKey="Leshel Hauzeneder M" first="Melanie" last="Leshel-Hauzeneder">Melanie Leshel-Hauzeneder</name>
</author>
</analytic>
<series><title level="j">MMW Fortschritte der Medizin</title>
<idno type="ISSN">1438-3276</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (administration & dosage)</term>
<term>Acetamides (therapeutic use)</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Clinical Trials, Phase II as Topic</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Cytokines (blood)</term>
<term>Endothelium, Vascular (physiopathology)</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Fibrinogen (analysis)</term>
<term>Germany (epidemiology)</term>
<term>Humans</term>
<term>Influenza, Human (blood)</term>
<term>Influenza, Human (complications)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (mortality)</term>
<term>Influenza, Human (physiopathology)</term>
<term>Neuraminidase (administration & dosage)</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Oseltamivir</term>
<term>Placebos</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acétamides (administration et posologie)</term>
<term>Acétamides (usage thérapeutique)</term>
<term>Allemagne (épidémiologie)</term>
<term>Antienzymes (administration et posologie)</term>
<term>Antienzymes (usage thérapeutique)</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Cytokines (sang)</term>
<term>Endothélium vasculaire (physiopathologie)</term>
<term>Essais cliniques de phase II comme sujet</term>
<term>Essais cliniques de phase III comme sujet</term>
<term>Facteurs temps</term>
<term>Fibrinogène (analyse)</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (mortalité)</term>
<term>Grippe humaine (physiopathologie)</term>
<term>Grippe humaine (sang)</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Oséltamivir</term>
<term>Placebo</term>
<term>Résultat thérapeutique</term>
<term>Sialidase (administration et posologie)</term>
<term>Sialidase (antagonistes et inhibiteurs)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Fibrinogen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acétamides</term>
<term>Antienzymes</term>
<term>Antiviraux</term>
<term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Fibrinogène</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Endothélium vasculaire</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Endothelium, Vascular</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Cytokines</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acétamides</term>
<term>Antienzymes</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials, Phase II as Topic</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Humans</term>
<term>Oseltamivir</term>
<term>Placebos</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Essais cliniques de phase II comme sujet</term>
<term>Essais cliniques de phase III comme sujet</term>
<term>Facteurs temps</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Oséltamivir</term>
<term>Placebo</term>
<term>Résultat thérapeutique</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15101538</PMID>
<DateCompleted><Year>2005</Year>
<Month>05</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1438-3276</ISSN>
<JournalIssue CitedMedium="Print"><Volume>145</Volume>
<Issue>13</Issue>
<PubDate><Year>2003</Year>
<Month>Mar</Month>
<Day>27</Day>
</PubDate>
</JournalIssue>
<Title>MMW Fortschritte der Medizin</Title>
<ISOAbbreviation>MMW Fortschr Med</ISOAbbreviation>
</Journal>
<ArticleTitle>[Highly selective virostatic therapy. Influenza wave could have been stopped].</ArticleTitle>
<Pagination><MedlinePgn>54-5</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leshel-Hauzeneder</LastName>
<ForeName>Melanie</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Hochselektive Virostatikatherapie. Grippewelle hätte gestoppt werden können.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>MMW Fortschr Med</MedlineTA>
<NlmUniqueID>100893959</NlmUniqueID>
<ISSNLinking>1438-3276</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9001-32-5</RegistryNumber>
<NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15101538</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=ExplorPubmed/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000530 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000530 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= *** parameter Area/wikiCode missing *** |area= ExplorPubmed |flux= Main |étape= Curation |type= RBID |clé= pubmed:15101538 |texte= [Highly selective virostatic therapy. Influenza wave could have been stopped]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:15101538" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ExplorPubmed
This area was generated with Dilib version V0.6.35. |